Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855718 | 0.92 | MDM2 (0.46) | CASP3MDM4TP53KMT2AMDM2 | |
| Succinic Acid SCHEMBL7574433 | 0.89 | MDM2 (0.44) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29401520 | 0.86 | CASP3 (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL20511461 | 0.86 | CASP3 (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL20511460 | 0.86 | CASP3 (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL23157052 | 0.86 | CASP3 (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL19900835 | 0.86 | KMT2A (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL19900833 | 0.86 | KMT2A (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL8035574 | 0.85 | MDM4 (0.55) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL31714219 | 0.85 | MDM4 (0.55) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732266-B2 | RNAi constructs for inhibiting ASGR1 expression and methods of use thereof | AMGEN INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732266-B2 | RNAi constructs for inhibiting ASGR1 expression and methods of use thereof | ASGR1, LDLR, SCARB1 | CASP3 3875/4885MDM4 4106/4885TP53 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.